EPCAM (Epithelial Cell Adhesion Molecule), also known as CD326, is a transmembrane glycoprotein that mediates Ca²⁺-independent homotypic adhesion in epithelial tissues. It is highly expressed on the basolateral surface of most normal epithelial cells and is markedly overexpressed in a wide range of carcinomas (e.g., colorectal, breast, and ovarian cancers). Beyond its role in adhesion and signaling, EPCAM serves as a definitive marker for isolating circulating tumor cells (CTCs), enabling liquid biopsy-based cancer diagnostics and monitoring. Therapeutically, it is a validated target for bispecific antibodies (e.g., catumaxomab) and CAR-T cell therapies, leveraging its dense surface expression on tumors to direct potent anti-tumor immune responses.